Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-002632-17 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of the study was to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) particpants treated with Mavenclad® for 2 years (24 months).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mavenclad® | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mavenclad® | Drug | Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) Physical Health Composite Summary and Mental Health Composite Summary Scores at Month 24 | The MSQOL-54 was a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. This 54-item instrument generates 12 sub-scales along with two summary scores, and two additional single-item measures. Sub-scales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The two summary scores physical health and mental health are derived from a weighted combination of scale scores. Each composite summary score has a range from 0-100 where higher scores indicate better QOL. A positive change from baseline indicates improvement. | Baseline, Month 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment Global Satisfaction Determined by Treatment Satisfaction Questionnaire Medication Version 1.4 (TSQM v1.4) Scale at Month 6 | TSQM version 1.4 was a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. It comprises of 14 items assessing the following 4 domains: effectiveness (questions: 1-3), side effects (questions: 4-8), convenience (questions: 9-11), global satisfaction (questions:12-14). Global Satisfaction- Question 12 scored as 1 (not at all confident) to 5 (extremely confident); question 13 scored as 1 (not at all certain) to 5 (extremely certain); and question 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Responsible | Merck KGaA, Darmstadt, Germany | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kepler Universitätsklinikum | Linz | 4021 | Austria | |||
| Paracelsus Medical University Salzburg |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41806309 | Derived | Brochet B, Langdon D, Havrdova EK, Lechner-Scott J, Montalban X, Patti F, Piehl F, Solari A, Hupperts R, Alexandri N, Lehn A, Smyk A, Selmaj K; CLARIFY-MS Investigators. Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study. Neurol Ther. 2026 Mar 10. doi: 10.1007/s40120-026-00897-0. Online ahead of print. | |
| 37978852 |
| Label | URL |
|---|---|
| Trial Awareness and Transparency website | View source |
Not provided
We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union
Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.
A total of 485 participants were enrolled in the study from different trial sites across Poland, Czechia, Slovakia, Hungary, Lithuania, Austria, Denmark, Finland, Sweden, Norway, Italy, Spain, Portugal, Greece, France, Netherlands, United Kingdom of Great Britain and Northern Ireland, and Belgium. Out of 485 participants, three participants were enrolled, but did not receive study medication.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Mavenclad® | Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 14, 2018 | Nov 9, 2022 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| At Month 6 |
| Salzburg |
| Austria |
| Eva Maida | Vienna | Austria |
| Cliniques Univ. St.-Luc | Brussels | 1200 | Belgium |
| UZ Antwerpen | Edegem | 2650 | Belgium |
| Clinique Saint Pierre | Ottignies | 1340 | Belgium |
| FN u sv. Anny Brno | Brno | 65691 | Czechia |
| FN Hradec Kralove | Choceň | 56501 | Czechia |
| Nemocnice Jihlava, p.o. | Jihlava | 586 33 | Czechia |
| Fakultni nemocnice Olomouc | Olomouc | 779 00 | Czechia |
| Fakultni nemocnice Ostrava (11573) | Ostrava | 70852 | Czechia |
| Faculty Hospital Kralovske Vinohrad | Prague | 100 34 | Czechia |
| Vseobecna fakultni nemocnice v Praze (11163) | Prague | 128 08 | Czechia |
| Nemocnice Teplice | Teplice | 415 29 | Czechia |
| Aalborg Hospital | Aalborg | 9100 | Denmark |
| Glostrup University Hospital | Glostrup Municipality | DK-2600 | Denmark |
| Odense Univeristy Hospital | Odense | Denmark |
| Matthias Kant | Sønderborg | 6400 | Denmark |
| Helsinki University Central Hospital | Helsinki | 290 | Finland |
| Helsinki University Central Hospital | Helsinki | Finland |
| Terveystalo Mikkeli | Mikkeli | 50100 | Finland |
| Neo Research, Neuro NEO Oy | Turku | Finland |
| Centre hospitalier de la Côte Basque - Saint Léon | Bayonne | 64100 | France |
| Hopital Pellegrin | Bordeaux | 33076 | France |
| University Hospital of Caen | Caen | 14033 | France |
| CHRU de Lille | Lille | 59037 | France |
| Groupe Hospitalier de l'Institut Catholique de Lille - Centre Hospitalier Saint Philibert | Lomme | France |
| CHU de Nantes | Nantes | 44093 | France |
| Centre Hospitalier de Gonesse | Paris | 75013 | France |
| Hôpital de la Pitié-Salpétrière | Paris | 75013 | France |
| CHU de Poissy | Poissy | 78303 | France |
| CHU Hopital Gabriel Montpied | Puy-de-Dome | 63003 | France |
| Centre Universitaire de Rouen | Rouen | 76031 | France |
| Hopital Pierre-Paul Riquet - Neurologie | Toulouse | 31059 | France |
| CHU Tours - Hôpital Bretonneau | Tours | 37044 | France |
| Hos. Errikos Dynan | Athens | 11526 | Greece |
| 401 Army Hospital | Athens | 11527 | Greece |
| Athens Medical Centre | Athens | 11527 | Greece |
| Semmelweis Egyetem AOK | Budapest | 1083 | Hungary |
| Uzsoki Utcai Korhaz | Budapest | 1145 | Hungary |
| Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet | Budapest | 1204 | Hungary |
| University of Debrecen | Debrecen | 4032 | Hungary |
| VALEOMED Kft | Esztergom | 2500 | Hungary |
| Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór | Nyíregyháza | 4403 | Hungary |
| A.O.U. Ospedali Riuniti Umberto I | Ancona | Italy |
| Ospedale Binaghi, Università di Cagliari,ASL 8 - Centro Sclerosi Multipla | Cagliari | 09126 | Italy |
| Policlinico di Catania | Catania | 95125 | Italy |
| Ospedale San Raffaele Giglio | Cefalù | 90015 | Italy |
| Ospedale San Raffaele, IRCCS | Milan | 20127 | Italy |
| Instituto Nazionale Neurologico "Carlo Besta" | Milan | 20133 | Italy |
| A.O. Universitaria Federico II | Naples | 80131 | Italy |
| Seconda Univesità degli Studi di Napoli, AOU | Naples | Italy |
| Villa Sofia Hospital | Palermo | 90146 | Italy |
| Azienda Ospedaliera S. Camillo Forlanini (8025) | Roma | 00152 | Italy |
| Azienda Ospedaliera Sant'Andrea Università La Sapienza | Roma | 00189 | Italy |
| Neurological Center Of Latium | Roma | 00189 | Italy |
| Policlinico Tor Vergata | Roma | Italy |
| Hospital of Lithuanian University of Health Sciences Kaunas | Kaunas | 50161 | Lithuania |
| Klaipedos Ligonine | Kaunas | 50161 | Lithuania |
| Vilnius University Hospital Santariskiu Clinics | Vilnius | 8661 | Lithuania |
| Zuyderland | Sittard-Geleen | 6131 BG | Netherlands |
| Drammen Hospital | Drammen | 3004 | Norway |
| COPERNICUS Podmiot Leczn. Sp z o.o. | Gdansk | 80-803 | Poland |
| M.A. - LEK A.M.Maciejowscy SC. | Katowice | 40-571 | Poland |
| Centrum Neurologii K. Selmaj | Lodz | 90-153 | Poland |
| Uniwersytecki Szpital Kliniczny nr 1 i.m. Norberta Barlickie | Lodz | 90-153 | Poland |
| Centrum Medyczne Medyk | Lublin | 20-954 | Poland |
| Indywidualna Praktyka Lekarska Prof. Konrad Rejdak | Lublin | 20-954 | Poland |
| Instytut Psychiatrii i Neurologii | Warsaw | 02-957 | Poland |
| Hospital de Braga | Braga | 4710-243 | Portugal |
| Centro Hospitalar do Porto E.P.E. Hospital de Santo António | Porto | 4099-001 | Portugal |
| Univerzitna nemocnica Bratislava | Bratislava | 813 69 | Slovakia |
| Univerzitna nemocnica Martin | Martin | 036 01 | Slovakia |
| Fakultna nemocnica Nitra | Nitra | 950 01 | Slovakia |
| Fakultna nemocnica Trnava | Trnava | 917 75 | Slovakia |
| C.A.U. de León - H. de León | León | 24071 | Spain |
| Hospital Arnau de Vilanova | Lleida | 25198 | Spain |
| Hospital General Universitario Gregorio Marañón (5030) | Madrid | 28007 | Spain |
| H. U. Quirónsalud Madrid | Madrid | 28040 | Spain |
| Hospital Universitario de Getafe | Madrid | 28905 | Spain |
| Hospital Virgen de la Arrixaca | Murcia | 30120 | Spain |
| Hospital de Sant Joan Despí Moisès Broggi | Sant Joan Despí | 08970 | Spain |
| Hospital Universitario Nuestra Senora de la Candelaria (4776) | Santa Cruz de Tenerfie | 38010 | Spain |
| Complejo Hospitalario Universitario de Santiago | Santiago de Compostela | 15706 | Spain |
| Hospital Universitario Virgen del Rocio - Servicio de Oncologia | Seville | 41013 | Spain |
| Karlstad Hospital (8232) | Karlstad | 651 86 | Sweden |
| Motala Hospital (11119) | Motala | 59185 | Sweden |
| Institute of Neurological Sciences | Glasgow | G51 4TF | United Kingdom |
| Institute of Neurological Sciences | Glasgow | United Kingdom |
| GM LCRN - Great Manchester Local Clinical Research Network | Manchester | M13 9WL | United Kingdom |
| The Newcastle Hospitals NHS Foundation Trust | Newcastle upon Tyne | NE1 4LP | United Kingdom |
| Morriston Hospital (4232) | Swansea West Glamorgan | SA6 6NL | United Kingdom |
| Derived |
| Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, Montalban X, Kubala Havrdova E. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Mult Scler. 2023 Dec;29(14):1808-1818. doi: 10.1177/13524585231205962. Epub 2023 Nov 18. |
| Medical Information Location Map - Med Info Contacts | View source |
| Full Analysis Set (FAS) | Full Analysis Set (FAS) consisted of all participants from the Intent-to-treat (ITT [ITT population included all participants classified as eligible]) set treated with at least one dose of study medication. |
|
| Safety Analysis Set (SAS) | SAF consisted of all participants treated with at least one dose of study medication. |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
FAS consisted of all participants from the ITT set treated with at least one dose of study medication.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Mavenclad® | Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) Physical Health Composite Summary and Mental Health Composite Summary Scores at Month 24 | The MSQOL-54 was a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. This 54-item instrument generates 12 sub-scales along with two summary scores, and two additional single-item measures. Sub-scales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The two summary scores physical health and mental health are derived from a weighted combination of scale scores. Each composite summary score has a range from 0-100 where higher scores indicate better QOL. A positive change from baseline indicates improvement. | FAS consisted of all participants from the ITT set treated with at least one dose of study medication. Here, "overall number of participants analyzed" signifies number of participants who were evaluable for this outcome measure. | Posted | Least Squares Mean | Standard Error | Score on a Scale | Baseline, Month 24 |
|
|
| ||||||||||||||||||||||||||||||||
| Secondary | Treatment Global Satisfaction Determined by Treatment Satisfaction Questionnaire Medication Version 1.4 (TSQM v1.4) Scale at Month 6 | TSQM version 1.4 was a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. It comprises of 14 items assessing the following 4 domains: effectiveness (questions: 1-3), side effects (questions: 4-8), convenience (questions: 9-11), global satisfaction (questions:12-14). Global Satisfaction- Question 12 scored as 1 (not at all confident) to 5 (extremely confident); question 13 scored as 1 (not at all certain) to 5 (extremely certain); and question 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. | FAS consisted of all participants from the ITT set treated with at least one dose of study medication. Here, "overall number of participants analyzed" signifies number of participants who were evaluable for this outcome measure. | Posted | Least Squares Mean | Standard Error | Score on a Scale | At Month 6 |
|
From Baseline up to Month 24
Safety Analysis Set (SAF) consisted of all participants treated with at least one dose of study medication.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Mavenclad® | Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year. | 0 | 482 | 26 | 482 | 375 | 482 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Inguinal hernia | Gastrointestinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| COVID-19 pneumonia | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Lyme disease | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Clavicle fracture | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Concussion | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Medication error | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Upper limb fracture | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Angiomyolipoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Ovarian cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Epilepsy | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Ischaemic stroke | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Multiple sclerosis relapse | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Panic disorder | Psychiatric disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Cervical dysplasia | Reproductive system and breast disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Ovarian cyst | Reproductive system and breast disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Ovulation pain | Reproductive system and breast disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Hyperventilation | Respiratory, thoracic and mediastinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Aortic aneurysm rupture | Vascular disorders | MedDRA version 24.0 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lymphopenia | Blood and lymphatic system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Oral herpes | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Communication Center | Merck KGaA, Darmstadt, Germany | +49-6151-72-5200 | service@emdgroup.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 21, 2021 | Nov 9, 2022 | SAP_001.pdf |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017338 | Cladribine |
| ID | Term |
|---|---|
| D015762 | 2-Chloroadenosine |
| D000241 | Adenosine |
| D011684 | Purine Nucleosides |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D003839 | Deoxyadenosines |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D012263 | Ribonucleosides |
Not provided
Not provided
| Unknown or Not Reported |
|
| Not collected at this site |
|
| Units | Counts |
|---|---|
| Participants |
|
|